Welcome to our dedicated page for Neurosense Therapeutics SEC filings (Ticker: NRSNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to present SEC-related information for NeuroSense Therapeutics Ltd. in connection with the NRSNW symbol. NeuroSense is a clinical-stage biotechnology company that describes its focus as discovering and developing treatments for debilitating neurodegenerative diseases, including ALS, Alzheimer's disease and Parkinson's disease, among others. Its lead candidate, PrimeC, is a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, designed to target multiple mechanisms involved in ALS and Alzheimer's disease.
While no specific SEC filings are listed in the available data for this symbol, investors commonly look to regulatory documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K to better understand a company’s business description, risk factors and program updates. For a company like NeuroSense, such filings can provide additional detail on its clinical-stage pipeline, including PrimeC, and on its strategy to develop combined therapies targeting multiple pathways associated with neurodegenerative diseases.
On Stock Titan, the SEC filings page is designed to surface these documents as they become available from EDGAR, along with AI-powered summaries that explain key sections in clearer language. When filings are present, users can review disclosures on topics such as clinical development progress, research activities and other company updates, and can also access insider transaction reports on Form 4 when applicable.
As filings for NRSNW are recorded, this page will help organize them by form type and date, and AI-generated insights will highlight important points so readers can more quickly understand how NeuroSense describes its business, programs and associated risks in its official SEC documents.
NeuroSense Therapeutics Ltd. filed a Form 6-K to furnish a press release announcing that the Brazilian Patent and Trademark Office has granted Brazilian Patent No. 112024007727-6 covering the company’s proprietary PrimeC composition, a fixed-dose oral combination of ciprofloxacin and celecoxib.
The patent, which follows corresponding approvals in the U.S. and Australia, provides protection for PrimeC in Brazil and extends patent coverage through October 2042, supporting long-term development and potential commercialization in amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative indications. NeuroSense describes PrimeC as a synchronized, extended-release, multi-target therapy and notes it is preparing to initiate the PARAGON Phase 3 pivotal trial in ALS after positive Phase 2b results and FDA clearance.
NeuroSense Therapeutics Ltd. reported that Nasdaq has notified the company it is not in compliance with two continued listing standards. The company’s ordinary shares closed below the required $1.00 minimum bid price for 30 consecutive business days from February 18 through March 31, 2026.
Over the same period, NeuroSense’s market value of listed securities was below Nasdaq’s $35 million minimum. These notices do not immediately affect trading; the shares and warrants remain on The Nasdaq Capital Market under “NRSN” and “NRSNW.”
NeuroSense has 180 calendar days, until September 29, 2026, to regain compliance. It must achieve at least $1.00 closing bid and $35 million MVLS for a minimum of 10 consecutive business days for each metric, subject to Nasdaq’s discretion.
Eisenberg Or reported acquisition or exercise transactions in this Form 4 filing.
NeuroSense Therapeutics Ltd. Chief Financial Officer Eisenberg Or received a grant of 200,000 restricted Ordinary Shares as equity compensation. The shares were granted at $0.00 per share and will vest in equal quarterly installments over a two-year period starting on March 26, 2026, provided he continues to serve the company on each vesting date. Following this award, he directly holds 1,254,050 Ordinary Shares.
NeuroSense Therapeutics Ltd. filed an initial Form 3 for Chief Financial Officer Or Eisenberg, detailing his existing equity interests in the company. The filing reports direct ownership of 573,126 Ordinary Shares, along with fully vested options and warrants over additional Ordinary Shares.
The Form 3 shows options to purchase 21,000 Ordinary Shares at an exercise price of $0.033 per share, expiring on June 21, 2031, which are noted as fully vested and exercisable. It also lists warrants to purchase 66,666 Ordinary Shares at an exercise price of $0.75 per share, expiring on August 14, 2029, acquired in an August 15, 2024 private placement.
NeuroSense Therapeutics Ltd. director Mandil-Levin Revital filed an initial ownership report showing option and share holdings in the company. The filing lists options to purchase 72,000 Ordinary Shares at an exercise price of $1.43 per share, expiring on March 10, 2032, which are fully vested and exercisable.
The report also shows direct ownership of several blocks of Ordinary Shares, including 52,526 shares, 60,000 shares, and 76,844 restricted shares. Certain restricted shares vest on December 30, 2026 and January 30, 2027, subject to continued service and potential acceleration upon achieving specified business milestones.
NeuroSense Therapeutics reported full-year 2025 results and highlighted major progress for its ALS drug candidate PrimeC. The Phase 2b study showed about 33% slowing in disease progression over 18 months, and follow-up survival data indicated a 65% reduction in risk of death with more than a 14‑month median survival benefit. PrimeC received FDA clearance in November 2025 to initiate the PARAGON Phase 3 ALS trial, and results were published in JAMA Neurology.
Financially, 2025 research and development expenses were $6.2 million and general and administrative expenses were $4.9 million, leading to a net loss of $11.1 million, or $0.44 per share. As of December 31, 2025, cash and cash equivalents were $166 thousand, down from $3.4 million a year earlier, and shareholders’ equity stood at a deficit of $1.6 million.
NeuroSense Therapeutics Ltd. reports in its annual filing that it is a clinical-stage biotech focused on PrimeC for ALS, with no approved products and no material revenue. As of December 31, 2025, it held $0.2 million in cash and cash equivalents and recorded a $11.1 million net loss for 2025, following a $10.2 million net loss in 2024. Its auditors include a going concern reference, as the company will require substantial additional financing to continue operations, complete clinical trials, obtain regulatory approvals and commercialize its pipeline. The company highlights significant risks around funding, clinical and regulatory uncertainty, intense competition in neurodegenerative diseases, reliance on third-party manufacturers and CROs, and protection of its intellectual property. NeuroSense recently shifted its accounting framework to U.S. GAAP and is preparing a pivotal Phase 3 trial of PrimeC for ALS after receiving FDA clearance, while also exploring an expedited approval pathway with Health Canada.
Russek-Blum Niva reported acquisition or exercise transactions in this Form 4 filing.
NeuroSense Therapeutics Ltd. reported that Chief Technology Officer Niva Russek-Blum received a grant of 200,000 Ordinary Shares. These are restricted shares awarded as compensation at a stated price of $0.00 per share, increasing her direct holdings to 467,953 Ordinary Shares after the grant.
The restricted shares vest in equal quarterly installments over a two-year period, starting from the grant date of March 26, 2026, and depend on her continued service with the company. Footnotes note that, to qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the company’s 2018 Share Incentive Plan must be registered in the name of a trustee.
NeuroSense Therapeutics Ltd. Chief Technology Officer Niva Russek-Blum filed an initial ownership report showing multiple equity holdings in the company. The filing lists 36,000 options to purchase ordinary shares at an exercise price of $2.18 per share, fully vested and exercisable, expiring on January 25, 2032.
It also reports several blocks of ordinary shares, including 39,881 shares, 35,000 shares and 183,072 shares held directly, plus 10,000 restricted share units. Footnotes note that certain restricted shares vest mostly in April 2027 with the remainder in October 2027, while the restricted share units vest on April 1, 2026, all subject to continued service and, for some awards, a business milestone.
NeuroSense Therapeutics Ltd. filed an initial ownership report showing that Chief Executive Officer and 10% owner Alon Ben-Noon holds several blocks of ordinary shares and warrants. He directly holds 3,175,266 Ordinary Shares, plus additional direct holdings of 641,524 and 360,777 Ordinary Shares. He also holds warrants to purchase 26,666 Ordinary Shares at an exercise price of $0.75 per share, expiring on August 14, 2029, and warrants to purchase 80,000 Ordinary Shares at an exercise price of $1.25 per share, expiring on December 4, 2029. Footnotes explain that these warrants and related shares were acquired in private placements on August 15, 2024 and December 5, 2024, and that certain restricted shares vest 75% on April 16, 2027 and May 19, 2027, with the remainder vesting later in 2027, subject to continued service and a business milestone.